1
Zhenping Zhu: Human antibodies specific to KDR and uses thereof. ImClone Systems Incorporated, Lerner David Littenberg Krumholz & Mentlik, March 3, 2009: US07498414 (37 worldwide citation)

The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, a ...


2
Zhu Zhenping: Human antibodies specific to kdr and uses thereof. Imclone Systems Incorporated, Zhu Zhenping, SOMERVILLE Deborah A, September 18, 2003: WO/2003/075840 (2 worldwide citation)

The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, a ...


3
Zhu Zhenping: Human antibodies specific to kdr and uses thereof. Imclone Systems, April 30, 2008: EP1916001-A2 (1 worldwide citation)

The application provides antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralize activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and ...


4
Zhenping Zhu: Human antibodies specific to KDR and uses thereof. ImClone, Averie K Hason, November 15, 2011: US08057791 (1 worldwide citation)

The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, a ...


5
Zhu Zhenping: Human antibodies specific to kdr and uses thereof. Imclone Systems, December 22, 2004: EP1487856-A2

The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, a ...


6
ZHU ZHENPING: ANTICORPS HUMAINS SPECIFIQUES DE KDR ET LEURS UTILISATIONS, HUMAN ANTIBODIES SPECIFIC TO KDR AND USES THEREOF. IMCLONE SYSTEMS INCORPORATED, IMCLONE, GOWLING LAFLEUR HENDERSON, April 16, 2013: CA2478169

The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, a ...


7
Zu Zhenping: Human antibodies specific to kdr and uses thereof. Imclone, March 23, 2011: EP2298346-A2

The invention provides antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralize activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and s ...


8
Zhenping Zhu: Human antibodies specific to kdr and uses thereof. Kenyon & Kenyon, October 20, 2005: US20050234225-A1

The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, a ...


9
Zhenping Zhu: Human antibodies specific to kdr and uses thereof. ImClone Systems Incorporated, Imclon, Lerner David Littenberg Krumholz & Mentlik, June 4, 2009: US20090142358-A1

The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, a ...


10